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Isolated heart cells are highly susceptible to the toxicity of catecholamine oxidation products, namely,
to catecholamine-glutathione adducts. Although cellular uptake and/or efflux of these products may
constitute a crucial step, the knowledge about the involvement of transporters is still very scarce. This
work aimed to contribute to the characterization of membrane transport mechanisms, namely, extraneuronal
monoamine transporter (EMT), the multidrug resistant protein 1 (MRP1), and P-glycoprotein (P-gp) in
freshly isolated cardiomyocytes from adult rats. These transporters may be accountable for uptake and/
or efflux of adrenaline and an adrenaline oxidation product, 5-(glutathion-S-yl)adrenaline, in cardiomyocyte
suspensions. Our results showed that 5-(glutathion-S-yl)adrenaline efflux was mediated by MRP1.
Additionally, we demonstrated that the adduct formation occurs within the cardiomyocytes, since EMT
inhibition reduced the intracellular adduct levels. The classical uptake2 transport in rat myocardial cells
was inhibited by the typical EMT inhibitor, corticosterone, and surprisingly was also inhibited by low
concentrations of another drug, a well-known P-gp inhibitor, GF120918. The P-gp activity was absent in
the cells since P-gp-mediated efflux of quinidine was not blocked by GF120918. In conclusion, this
work showed that freshly isolated cardiomyocytes from adult rats constitute a good model for the study
of catecholamines and catecholamines metabolites membrane transport. The cardiomyocytes maintain
EMT and MRP1 fully active, and these transporters contribute to the formation and efflux of 5-(glutathion-
S-yl)adrenaline. In the present experimental conditions, P-gp activity is absent in the isolated
cardiomyocytes.
Introduction
There is increasing evidence that catecholamine oxidation
may result in toxicity, namely, cardiotoxicity (1-8). In cardio-
myocytes, the oxidation process of adrenaline (ADR)1 initially
involves its conversion to o-quinone through o-semiquinone
intermediary (5). The o-quinone can react with glutathione
(GSH) to form GSH conjugates or be attacked by other
nucleophilic groups in the cells. We reported previously, for
the first time, the detection of 5-(glutathion-S-yl)adrenaline in
cardiomyocytes, even at ADR concentrations as low as 25 µM
(5). Moreover, we observed that this GSH adduct was found in
the incubation medium, leading to the hypothesis that a
transporter-mediated efflux could be present (5). Certain GSH
conjugates are reported to be toxic in many organs (9, 10). In
fact, they seem to be involved in the pathogenesis of Parkinson’s
disease (11, 12) and in the toxicity of illicit drugs, like 3,4-
methylenedioxymethamphetamine (MDMA) (13-15) or meth-
amphetamine (16).
Cardiomyocytes are able, as other cells, to use efflux
transporters to prevent the accumulation of compounds, leading
to a decrease in their intracellular concentration (17). In 1976,
a membrane-bound transporter, responsible for the efflux of
anticancer drugs in cancer cells, was found and termed perme-
ability glycoprotein (P-glycoprotein, P-gp) (18). P-gp conferred
cancer cells the phenotype of “multidrug resistance”. The
multidrug resistance cell phenotype classically refers to tumors
that are refractory to chemically unrelated cytotoxic agents, due
to active outward transport. The P-gp expression does not fully
account for all spectra of multidrug resistance. There are several
ATP-binding cassette (ABC) transporters involved in multidrug
resistance, including P-gp [MDR1/ABCB1 (18)], the multidrug
resistance protein 1 [MRP1/ABCC1 (19)], and the breast can-
cer resistance protein [ABCG2/BCRP/MXR/ABCP (20)]. These
transporters are located in the plasma membrane and extrude a
variety of drugs by using ATP (21-25).
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GSH-conjugated metabolites, once formed intracellularly, are
usually exported to be eliminated from the body or act on their
cellular targets. The efflux of GSH metabolites has already been
reported as a consequence of a phase II metabolism (26) and is
often mediated by the MRP1 transporter (23, 24). In addition
to drugs and GSH conjugates, MRP1 exports GSH and
glutathione disulfide (GSSG) and might thus have a role in
cellular responses to oxidative stress (26). To meet the criteria
for active transport, MRP1 transport should be ATP dependent,
saturable, temperature dependent, osmotically sensitive, and
inhibited by certain small molecules (e.g., MK-571) or MRP1-
specific monoclonal antibodies (26).
In this work, the ADR oxidation process was studied in
isolated cardiomyocytes, by following the membrane transport
of ADR and of its oxidation products. Catecholamines are
translocated across plasma membranes by transporters that
belong to two large families with mainly neuronal or extraneu-
ronal locations (27). A low-affinity, high-capacity uptake for
noradrenaline in the isolated perfused rat heart was found by
Iversen in 1965 (28), while in 1967, Malmfors demonstrated
by fluorescence microscopy that the myocytes are responsible
for this uptake process (29). Extraneuronal uptake of catechola-
mines is mediated by organic cation transporters (OCTs),
including OCT3, the classic corticosterone (CORT)-sensitive
extraneuronal monoamine transporter (EMT), traditionally
known as uptake2. Other transporters, like OCT1 and OCT2,
are involved in catecholamine uptake, mainly in liver or kidney
(30). The mRNA of plasma membrane monoamine transporter
(PMAT) has been described in the heart, and PMAT is also
able to transport organic cations (31, 32).
The present work aimed to characterize the functional
transporters in freshly isolated cardiomyocytes, namely, those
involved in the extraneuronal uptake of ADR and also the ABC
transporters, MRP1 and P-gp. In addition, the transporters
engaged in the formation and efflux of 5-(glutathion-S-yl)a-
drenaline were investigated in these cells.
Materials and Methods
Animals. Adult male Sprague-Dawley rats (Charles River
Laboratories, Barcelona, Spain) weighing 250-350 g were used.
The animals were housed in cages with a temperature- and
humidity-controlled environment and a 12 h light-dark cycle. Food
and water were provided ad libitum. Animal experiments were
licensed by the Portuguese General Directory of Veterinary
Medicine. Housing and experimental treatment of the animals were
in accordance with the Guide for the Care and Use of Laboratory
Animals from the Institute for Laboratory Animal Research (ILAR
1996). The experiments complied with current Portuguese laws.
Chemicals. All reagents used in this study were of analytical
grade. Collagenase type II was obtained from Worthington (Lake-
wood, NJ). Collagenase (type IA), N-(2-hydroxyethyl) piperazine-
N-(2-ethanesulfonic acid) (HEPES), ADR, verapamil, cyclosporin,
and CORT were obtained from Sigma-Aldrich (St. Louis, MO).
The MRP1 inhibitor, MK-571 {(E)-3-[[[3-[2-(7-chloro-2-quinoli-
nyl)ethenyl]phenyl]-[[3-dimethylamino)-3-oxopropyl]thio]meth-
yl]thio]propanoic acid} was obtained from Calbiochem (San Diego,
CA). GF120918 {9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-
tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-
carboxamide} was a generous gift from GlaxoSmithKline (Hert-
fordshire, United Kingdom). Dimethyl sulfoxide (DMSO) and
perchloric acid (HClO4) were purchased to Merck (Darmstadt,
Germany).
Isolation of Calcium-Tolerant Cardiomyocytes from Adult
Rat. Calcium-tolerant cardiomyocytes were isolated by Langendorff
retro perfusion of adult rat heart, as previously described (5). At
the beginning of the experiments, cell viability was always greater
than 60%, evaluated by the lactate dehydrogenase (LDH) leakage
assay and by microscopic evaluation of the cardiomyocytes
morphology. Incubations were performed in a water bath at 37 °C,
using a density of 2.5 × 105 cells/mL in modified Krebs-Henseleit
buffer supplemented with 1 mM CaCl2 (pH 7.4) and saturated, every
hour, with an airstream of carbogen.
After a preincubation of 30 min, the cells were then exposed to
the different compounds, namely, ADR; CORT, an EMT inhibitor;
cyclosporin, verapamil, and GF120918, P-gp inhibitors; quinidine,
an OCT1, OCT2, and PMAT inhibitor and P-gp substrate; and MK-
571, a MRP1 inhibitor, through a 3 h time study.
Sample Treatment. At the end of the 3 h incubation, cell
samples were obtained after centrifugation of cardiomyocytes
suspensions at 18g for 2 min. The pellet was washed twice with 1
mL of modified Krebs-Henseleit buffer supplemented with 1 mM
CaCl2, centrifuged at 18g for 2 min, and finally treated according
to the different determinations. Washing solutions obtained after
centrifugation were discarded.
HPLC/EC and HPLC/UV Analysis. The quantification of ADR
and of the adrenaline-GSH adduct in the cardiomyocytes was
performed using a HPLC instrument equipped with an electro-
chemical detector (EC), through a previously validated method (33).
Quinidine determination was performed using the HPLC instrument
coupled to UV detector, at 230 and 251 nm, according to the work
performed by Varma and co-workers (34).
Study of the Role of EMT in the Cardiomyocytes. To test
whether EMT was involved in ADR uptake into cardiomyocytes,
an inhibitor of uptake2, CORT, was tested at a final concentration
of 100 µM (35). Cardiomyocytes were preincubated with CORT
for 30 min, followed by an exposure to two different concentrations
of ADR, 10 (concentration of ADR for which the GSH-adduct is
not detectable in the cells) and 500 µM, for 3 h.
Also to appraise whether adrenaline-GSH adduct could be a
substrate of EMT, the cardiomyocytes were exposed to 14 µM
preformed 5-(glutathion-S-yl)adrenaline with and without CORT
(100 µM). The synthesis and isolation of the ADR adduct with
GSH followed previously published methods (5).
MRP1 and 5-(Glutathion-S-yl)adrenaline. After the preincu-
bation period, the cardiomyocytes were incubated with 500 µM
ADR for 3 h, in either the presence or the absence of MK-571, a
leukotriene D4 receptor antagonist, and a MRP1 inhibitor (10 µM)
(17). This experiment aimed to evaluate the involvement of MRP1
in the 5-(glutathion-S-yl)adrenaline efflux from the cardiomyocytes.
Measurement of Total GSH (GSHt) and GSSG Levels. In
cardiomyocytes, the GSHt and GSSG were determined to appraise
the interference of the MRP1 inhibitor in their values. The
cardiomyocytes were subjected to the sample treatment previously
described, acidified with 5% HClO4, and centrifuged, and the
supernatant obtained was used for the measurements by the DTNB-
GSSG redutase recycling assay (36).
Evaluation of P-gp Efflux. To evaluate the P-gp activity in
cardiomyocytes, a P-gp substrate, quinidine (100 µM), was used.
Cardiomyocytes were preincubated for 30 min with quinidine, after
which they were exposed to GF120918 (10 µM). Quinidine levels
in the cardiomyocytes were evaluated by HPLC/UV.
Evaluation of ADR and 5-(Glutathion-S-yl)adrenaline
Levels in Cardiomyocytes Exposed to P-gp and OCT
Inhibitors. P-gp inhibitors GF120918, cyclosporin, or verapamil
were used to evaluate their interference in either 5-(glutathion-S-
yl)adrenaline formation or efflux (17, 37, 38). Each experiment
entailed a control group (no treatment), an ADR group, an ADR
plus P-gp inhibitor group, and a P-gp inhibitor group. When using
GF120918 or cyclosporin, a group with only the vehicle (DMSO)
was also tested. Cardiomyocytes were incubated with 500 µM ADR
in the presence and absence of P-gp inhibitors: 0.1, 1, and 10 µM
GF120918, 10 µM verapamil, or 3 and 12 µM cyclosporin. Studies
with 20 µM GF120918 were also performed.
Quinidine is a P-gp substrate and also an OCT1, OCT2, and
PMAT inhibitor (31). It was used to evaluate the influence of
transporters other than EMT in ADR transport in freshly isolated
cardiomyocytes. Cardiomyocytes were preincubated with quinidine
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for 30 min, followed by incubation with 500 µM ADR. The cellular
content of ADR and 5-(glutathion-S-yl)adrenaline was monitored
by HPLC.
LDH Leakage Assay. LDH leakage assay was performed
directly in the cardiomyocyte suspensions to evaluate the level of
cell injury at time 0 h (immediately after addition of the compounds)
and after the 3 h incubation time in all treatments, as previously
described (5).
Statistical Analysis. Results are given as means ( the standard
deviation (SD) from 4 to 6 independent experiments with suspen-
sions of cardiomyocytes obtained from 4 to 6 different rats.
Nonparametric tests were used. Statistical comparisons between
groups were performed with a Kruskal-Wallis test (one-way
ANOVA on Ranks) followed by the Student-Newman-Keuls post
hoc test, once a significant p had been obtained.
When only two treatment groups were compared, the Mann-
Whitney Rank Sum test was used. Details of the statistical analysis
are described in each figure legend. Significance was accepted at p
values of <0.05.
Results
Inhibition of EMT Leads to the Decrease in Intracel-
lular Content of ADR and 5-(Glutathion-S-yl)adrenaline. The
specific accumulation of ADR in cardiomyocytes, when incu-
bated with 10 or 500 µM ADR, was reduced by the EMT
inhibitor, CORT (100 µM). After incubation for 3 h, a
significantly higher concentration of intracellular ADR content
was found in 10 µM ADR group (0.51 ( 0.23 µM ADR) when
compared with the 10 µM ADR plus CORT (0.03 ( 0.06 µM
ADR) (Figure 1A). The same tendency was found in the 500
µM ADR group. The intracellular ADR concentration was 25.5
( 9.5 and 3.31 ( 0.99 µM in cells incubated with 500 µM
ADR and 500 µM ADR plus CORT, respectively (Figure 1A).
As a product of ADR oxidation, 5-(glutathion-S-yl)adrenaline
levels were shown to be dependent on the intracellular ADR
concentration (5), as this work further demonstrates. In fact,
with ADR incubation, 5-(glutathion-S-yl)adrenaline was evalu-
ated in the cardiomyocytes, and its concentration was signifi-
cantly reduced in the 500 µM ADR plus CORT [0.049 ( 0.014
µM 5-(glutathion-S-yl)adrenaline], when compared with 500 µM
ADR [0.354 ( 0.106 µM 5-(glutathion-S-yl)adrenaline] (Figure
1B).
DMSO (2%) was required to prepare CORT solutions, and
it did not diminish the ADR transport into the cardiomyocytes
or the 5-(glutathion-S-yl)adrenaline synthesis within the cells
(data not shown). No interfering peaks in the chromatogram
were found in control group, CORT, or vehicle group (data not
shown).
To evaluate the possible involvement of EMT in the transport
of preformed 5-(glutathion-S-yl)adrenaline into the cells, we
incubated the cardiomyocytes with preformed 5-(glutathion-S-
yl)adrenaline (14 µM) with or without CORT. No differences
were observed between the two groups (data not shown).
MRP1 System Is Involved in the Efflux of 5-(Gluta-
thion-S-yl)adrenaline and GSSG. As MRP1 has been associ-
ated with the efflux of GSH and GSH conjugates (17, 26), its
contribution toward the efflux of 5-(glutathion-S-yl)adrenaline
was investigated in freshly isolated cardiomyocytes. Incubation
of these cardiomyocytes with MK-571, a MRP1 inhibitor, led
to the intracellular increase in 5-(glutathion-S-yl)adrenaline at
3 h in the ADR plus MK-571 group [0.462 ( 0.109 µM
5-(glutathion-S-yl)adrenaline] when compared with only ADR-
treated cells [0.285 ( 0.110 µM 5-(glutathion-S-yl)adrenaline]
(Figure 2A).
Neither MK-571 nor its vehicle (DMSO 0.2%) affected ADR
levels within the cardiomyocytes (data not shown). The cellular
GSHt (GSH + GSSG) and GSSG content was measured under
MRP1 inhibition by MK-571. The cardiomyocytes in the ADR
group had no change in GSSG levels, when compared to control,
while GSSG significantly increased in the ADR plus MK-571
group when compared to control, ADR, or MK-571 groups
(Figure 2B). The ADR group had a significant decrease in GSHt
(Figure 2C). When MK-571 was also added to ADR, the GSHt
in the cardiomyocytes increased when compared to the group
with only ADR (Figure 2C). Neither MK-571 nor the vehicle
(DMSO 0.2%) affected GSSG or GSHt levels of cardiomyocytes
(data not shown).
P-gp Inhibitor Affected EMT in Freshly Isolated Car-
diomyocytes. To investigate other efflux transporters besides
MRP1 or EMT, P-gp activity was evaluated in the isolated cells.
The P-gp substrate, quinidine at 100 µM, and a P-gp inhibitor,
GF120918 (10 µM), were used. Although quinidine was found
in the cardiomyocytes, no increase in its concentration was
observed when the P-gp inhibitor was added (data not shown).
In independent experiments and to investigate the interference
of P-gp inhibitors in the 5-(glutathion-S-yl)adrenaline formation
or efflux, the cardiomyocytes were incubated with ADR (500
µM) with or without P-gp inhibitors or substrates, namely,
cyclosporin, verapamil, quinidine, and GF120918.
GSH adduct concentration in cardiomyocytes incubated
simultaneously with 500 µM ADR and 10 µM GF120918
decreased significantly [0.081 ( 0.028 µM 5-(glutathion-S-
yl)adrenaline] when compared to ADR [0.373 ( 0.112 µM
5-(glutathion-S-yl)adrenaline]. Additional incubation with MK-
571 (500 µM ADR plus 10 µM GF120918 and 10 µM MK-
Figure 1. (A) Intracellular levels of adrenaline (ADR) in cardiomyo-
cytes incubated for 3 h with 10 µM ADR, 10 µM ADR with CORT at
100 µM, 500 µM ADR, and 500 µM ADR with CORT. Results are
presented as means (µM) ( SD from six different experiments.
Statistical comparisons were made using Kruskal-Wallis test followed
by the Student-Newman-Keuls post hoc test (**p < 0.01 vs the
respective group with no CORT). (B) Intracellular levels of 5-(glu-
tathion-S-yl)adrenaline formed in cardiomyocytes exposed to 500 µM
ADR and 500 µM ADR with CORT at 100 µM for 3 h. Statistical
comparisons were made using the Mann-Whitney Ram Sum test (*p
< 0.05 vs 500 µM ADR).
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571) resulted in a slight increase [0.091 ( 0.048 µM 5-(glu-
tathion-S-yl)adrenaline] (Figure 3A).
After observing the decrease of 5-(glutathion-S-yl)adrenaline
in cardiomyocytes when incubated with GF120918, we decided
to study the possible inhibition of EMT by GF120918. We
measured the ADR concentration in cardiomyocytes when using
10 µM GF120918. The concentration of intracellular ADR was
greatly decreased in the ADR plus GF120918 group when
compared to ADR group (Figure 3B). This showed that
GF120918 severely decreased ADR levels within the cardi-
omyocytes, which was reflected in the intracellular formation
of 5-(glutathion-S-yl)adrenaline. When adding CORT or MK-
571 to ADR plus GF120918, no significant differences were
found in ADR content (Figure 3B). To verify whether the
GF120918 inhibition of EMT was dose dependent, we incubated
the cardiomyocytes with 500 µM ADR with two other concen-
trations of GF120918, 1 and 0.1 µM (37, 38). In this study, we
showed that 10 µM GF120918 decreased ADR within the cells
to about 12% when compared to ADR group, while 1 µM
GF120918 resulted in a decrease to about 58% (Figure 3C).
Studies with 20 µM GF120918 did not provide statistical
differences in ADR intracellular concentration when compared
to 10 µM GF120918 (data not shown). No statistical difference
was found between the ADR plus 0.1 µM GF120918 group
and the ADR group.
Intracellular ADR content in cardiomyocytes was also evalu-
ated after incubation with quinidine and cyclosporin. Quinidine
and cyclosporin had no significant effect in intracellular ADR
(Figure 3D) and GSH adduct content (data not shown). No
interfering chromatographic peaks were found in cyclosporin
group, quinidine group, GF120918 group, or the vehicle group
(data not shown).
Cellular Viability. ADR (maximum concentration of 500
µM), GF120918, MK-571, DMSO (maximum concentration of
2%), CORT, quinidine, and cyclosporin were not cytotoxic as
verified using the LDH leakage test (data not shown). Verapamil
in concentrations described to inhibit P-gp (10 µM) (17, 39)
lead to decreased viability. As such, verapamil was not further
used in our studies.
Discussion
In the present work, we started by characterizing EMT in
freshly isolated cardiomyocytes, with a well-known EMT
inhibitor, CORT (35). By using two very distinct ADR
concentrations, 500 and 10 µM, we were able to demonstrate
that these cells are a suitable model to investigate EMT and,
therefore, its role in the oxidation process of catecholamines
within the cells. Our previous work has shown the ability of
ADR to undergo a complex oxidation process, leading to
formation of a glutathionyl adduct [5-(glutathion-S-yl)adrena-
line] (Figure 4) in the cardiomyocytes, still detectable with ADR
concentrations as low as 25 µM (5). In the present study, we
found further evidence that GSH adduct is formed within the
cells, as a marked decrease of intracellular 5-(glutathion-S-
yl)adrenaline was observed when CORT blocked ADR uptake
(Figure 1B). This depletion is directly associated to the decrease
of ADR within the cardiomyocytes. CORT decreased ADR
within the cells to about 13% when compared to ADR group
(Figure 1A), exactly the same reduction observed in the adduct
formation in ADR with CORT group. We excluded the inward
transport of the adduct through EMT, since incubating with
preformed 5-(glutathion-S-yl)adrenaline alone or with CORT
lead to no differences in the values of the referred adduct in
the cardiomyocytes.
The cytotoxicity of catechol-GSH adducts has been frequently
reported (6, 10, 14-16). As high values of 5-(glutathion-S-
yl)adrenaline were found in the incubation medium (5), we
assumed that a possible transporter for GSH conjugate efflux
could be present in cardiomyocytes with a conceivable protective
role (23). Thus, we decided to investigate the involvement of
ABC transporters in the efflux of GSH conjugates and further
elucidate the efflux transport mechanisms in freshly isolated
cardiomyocytes. GSH is a chemically reactive tripeptide and,
consequently, can form different types of adducts, namely, GSH-
thioethers, -thioesthers, and -mercaptides (23). GSH-conjugated
metabolites can be exported from the cells, their efflux being
often mediated by the MRP1 transporter. MRP1 is expressed
at moderate levels in most normal tissues, except in the liver,
where it is usually barely detectable (24, 26), conferring drug
resistance to tumor cells and protecting cells from toxic insults
Figure 2. (A) Intracellular levels of 5-(glutathion-S-yl)adrenaline in
calcium-tolerant rat cardiomyocytes exposed to 500 µM ADR and 500
µM ADR plus MK-571 (MK) at 10 µM for 3 h. Results are presented
as means ( SD from six different experiments. Statistical comparisons
were made using the Mann-Whitney Ram Sum test (*p < 0.05, ADR
vs ADR plus MK-571 group). (B) Intracellular GSSG levels in calcium-
tolerant rat cardiomyocytes in control group and groups exposed to
500 µM ADR and 500 µM ADR plus MK-571 for 3 h or MK-571
alone. Results are presented as means ( SD from four different
experiments. Statistical comparisons were made using Kruskal-Wallis
test, followed by the Student-Newman-Keuls post hoc test (*p <
0.05 vs 500 µM ADR; #p < 0.05 vs control; and $p < 0.05 vs MK-
571). (C) GSHt levels in calcium-tolerant rat cardiomyocytes in control
group and groups exposed to 500 µM ADR, 500 µM ADR plus MK-
571, and MK-571 at 3 h. Results are presented as means ( SD from
four different experiments. Statistical comparisons were made using
Kruskal-Wallis test, followed by the Student-Newman-Keuls post
hoc test (*p < 0.05 vs 500 µM ADR; #p < 0.05 vs control; and $p <
0.05 vs MK-571).
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(23, 24). In the present study, we have shown that MRP1 has
an important role in exporting 5-(glutathion-S-yl)adrenaline
formed by ADR oxidation, although we do not exclude the
involvement of other transporters, as well. When cardiomyocytes
were exposed to ADR and MK-571, the intracellular GSH
adduct (Figure 2A) and GSSG levels (and consequently GSHt)
(Figure 2B,C) significantly increased. Previous evidence sug-
gests that the decrease of GSH in the ADR group is related to
Figure 3. (A) Intracellular levels of 5-(glutathion-S-yl)adrenaline in cardiomyocytes exposed to 500 µM ADR, 500 µM ADR plus GF120918 (10
µM), and 500 µM ADR plus GF120918 plus MK-571 for 3 h. Statistical comparisons were made using Kruskal-Wallis test, followed by the
Student-Newman-Keuls post hoc test (**p < 0.01 vs 500 µM ADR) of six independent experiments. (B) Intracellular levels of ADR of myocytes
exposed to 500 µM ADR, 500 µM ADR with GF120918 (10 µM), 500 µM ADR with GF120918 and MK-571, 500 µM ADR with GF120918 and
CORT, and 500 µM ADR with CORT for 3 h. Statistical comparisons were made using Kruskal-Wallis test, followed by the Student-Newman-Keuls
post hoc test (**p < 0.01 vs 500 µM ADR) of six independent experiments. (C) Intracellular levels of ADR in cardiomyocytes after the incubation
with 500 µM ADR and 500 µM ADR with GF120918 (0.1, 1, and 10 µM) at 3 h. Results are presented as means ( SD from six different
experiments when compared to 500 µM ADR, which was set to 100%. Statistical comparisons were made using Kruskal-Wallis test, followed by
the Student-Newman-Keuls post hoc test (**p < 0.01 vs 500 µM ADR). (D) Intracellular levels of ADR in myocytes exposed to 500 µM ADR,
500 µM ADR with cyclosporine (CYC) at 12 µM, and 500 µM ADR with quinidine (QUIN) at 100 µM for 3 h. Results are presented as means
( SD from six different experiments when compared with 500 µM ADR, which was set to 100%.
Figure 4. Characterization of transport mechanisms in freshly isolated cardiomyocytes. The oxidation process of ADR involves the formation of
several reactive intermediaries and reactive species in cardiomyocytes. The oxidation process of ADR initially involves its conversion to o-quinone
that can react with GSH to form the corresponding GSH conjugates or react with other nucleophilic groups in the cells, namely, proteins. The
5-(glutathion-S-yl)adrenaline and GSSG are transported out of the cells by multidrug resistant protein 1 (MRP1). MRP1 is inhibited by MK-571.
EMT is active in these calcium-tolerant cardiomyocytes. EMT is blocked by CORT and GF120918, reported as a P-gp inhibitor. These cells after
isolation and incubation seem to maintain the characteristics of adult heart cells, since they show EMT and MRP1 active transport but no signs of
P-gp activity.
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the formation of reactive species (5), at the same time as the
formation of those reactive species was not inhibited by
exposition to adrenergic antagonists, prazosin, and propranolol
(our unpublished results). The cardiomyocytes exposure to ADR
increased intracellular GSSG, but cells protect themselves
through MRP1 efflux. It is feasible that the transport of GSSG
and 5-(glutathion-S-yl)adrenaline in the cardiomyocytes exposed
to ADR occurs through the same MRP1 (26).
Additionally, we aimed to gather more data about other active
transport mechanisms in freshly isolated cardiomyocytes, namely,
P-gp. The controversy whether cardiomyocytes normally have
functional P-gp is an actual subject. It is generally accepted
that, in the normal heart, P-gp is absent in cardiomyocytes, being
only expressed in endothelial cells of capillaries and arterioles
(40-42). The fact remains that several works showed that P-gp
inhibitors alter transport mechanisms in cardiomyocytes
(17, 39, 43). Some authors attribute this fallacious effect to the
isolation or culture of the cells, which become able to express
P-gp (44). We used a well-characterized P-gp substrate, quini-
dine (34), to determine whether P-gp activity was present in
our freshly isolated cardiomyocytes. With that objective, we
performed an efflux study, in which cells were incubated with
the P-gp substrate to ensure its intracellular distribution, followed
by the incubation with a P-gp inhibitor, GF120918 (37, 38).
The cells showed no signs of P-gp activity when exposed to
quinidine, since its intracellular concentration was not altered
by the P-gp inhibitor. This demonstrated that in what concerns
this specific transporter, the isolated cardiomyocytes retained
adult cardiac cells characteristics.
Another objective of this work was to evaluate the influence
of various transport inhibitors in the formation and efflux of
5-(glutathion-S-yl)adrenaline. When incubating ADR with P-gp
inhibitor GF120918, the 5-(glutathion-S-yl)adrenaline levels in
cardiomyocytes decreased dramatically, even with simultaneous
incubation with MK-571 (Figure 3A). With such an intriguing
result, further investigation was required, through the measure-
ment of intracellular ADR levels. Incubation of cardiomyocytes
with GF120918 at 10 µM resulted in an unexpected decrease
in intracellular ADR levels (down to 12%) (Figure 3B), thus
explaining the compromised 5-(glutathion-S-yl)adrenaline syn-
thesis. This ADR decrease was shown to be GF120918
concentration dependent. Noteworthy, even using a 500 times
higher concentration of ADR (500 µM), the GF120918 (1 µM)
had a significant inhibition effect upon ADR uptake mechanisms
(Figure 3C).
Using the same concentrations of ADR (500 µM), GF120918
was shown to be even more potent than the specific EMT
inhibitor, CORT. In fact, with a 10 times lower concentration
(10 µM), GF120918 decreased ADR within the cells to about
the same amount as CORT at 100 µM (Figure 3B). Even when
combining CORT (100 µM) and GF120918 (10 µM), intracel-
lular ADR is still detected (Figure 3B). This may reveal the
presence of an additional ADR uptake mechanism in this model.
A P-gp inhibitor (cyclosporin) and a P-gp substrate (quinidine)
were used to test their influence in ADR uptake in the isolated
cardiomyocytes. Cyclosporin (3 and 12 µM) had no effect in
ADR concentrations within the cardiomyocytes (Figure 3D).
Other transporters could be involved in the uptake of ADR in
cardiomyocytes, like PMAT (32). Quinidine is known to be a
P-gp subtstrate and also PMAT and OCT1 and -2 inhibitor (31).
In this experimental model, quinidine did not interfere with ADR
uptake. In the present concentrations and model, EMT seems
to have higher relevance in ADR transport. However, and as
ADR uptake was not fully inhibited, even by 20 µM GF120918
or by 10 µM GF120918 plus 100 µM CORT, it is conceivable
that other import mechanisms may be involved.
The present work has the merit of showing that caution must
be taken when using “specific” inhibitors that, in this particular
case, even at micromolar concentrations, inhibit other transport-
ers, namely, EMT. A decrease in EMT may lead to an
accumulation of catecholamines in the intersticial space with
possible toxic effects. The catecholamine transporters function
as part of the uptake and metabolizing systems primarily
responsible for inactivation of the transmitters, as the enzymes
involved in the inactivation of catecholamines are located
intracellularly (27). EMT impairment can lead to an increase
of catecholamine levels, leading to sustained sympathicomimetic
activation, which may affect many organs, inclusively the heart
with inauspicious toxic results (30, 45, 46). Moreover, the
inhibition of EMT has a higher influence in the inactivation of
ADR, since EMT favors ADR over noradrenaline or dopamine
(30). Notwithstanding, Yang and co-workers had shown that
CORT, a well-characterized uptake2 inhibitor, is a P-gp inhibitor
(47); the inverse relation with a P-gp inhibitor was never
considered until know, to the best of our knowledge.
Our short-term studies require higher concentrations of
catecholamines than the ones expected in vivo (46). To study
the transport at physiological concentrations, most of the
transport studies in isolated cells are performed with radio-
chemical analysis (35, 48), with the inherent problems related
to the storage, handling, and waste disposal of radioactive
materials. Even so, we showed that these isolated cardiomyo-
cytes perform well. Therefore, they are a reliable model for
studying ADR and its metabolite transport.
In conclusion, EMT is active in freshly isolated rat cardi-
omyocytes, thus incorporating ADR, which undergoes subse-
quent intracellular oxidation reactions (Figure 4). The oxidation
process of ADR involves the formation of many reactive
intermediaries and reactive species in cardiomyocytes, namely,
GSH adduct and GSSG. The 5-(glutathion-S-yl)adrenaline and
GSSG efflux in cardiomyocytes are carried out by MRP1 (Figure
4).
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